Institutional shares held 55.2 Million
687K calls
357K puts
Total value of holdings $1.69B
$21.1M calls
$11M puts
Market Cap $1.31B
41,663,000 Shares Out.
Institutional ownership 132.45%
# of Institutions 229


Latest Institutional Activity in JANX

Top Purchases

Q4 2024
Ra Capital Management, L.P. Shares Held: 10.4M ($327M)
Q4 2024
Paradigm Biocapital Advisors LP Shares Held: 3.52M ($111M)
Q4 2024
Cormorant Asset Management, LP Shares Held: 2.1M ($66.2M)
Q4 2024
Janus Henderson Group PLC Shares Held: 3.56M ($112M)
Q4 2024
Holocene Advisors, LP Shares Held: 1.02M ($32M)

Top Sells

Q4 2024
Orbimed Advisors LLC Shares Held: 759K ($23.9M)
Q4 2024
Hudson Bay Capital Management LP Shares Held: 30K ($945K)
Q4 2024
State Street Corp Shares Held: 1.27M ($40M)
Q4 2024
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Shares Held: 429K ($13.5M)
Q4 2024
Schonfeld Strategic Advisors LLC Shares Held: 110K ($3.45M)

About JANX

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.


Insider Transactions at JANX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.37M Shares
From 23 Insiders
Grant, award, or other acquisition 249K shares
Other acquisition or disposition 6.92K shares
Open market or private purchase 2.02M shares
Exercise of conversion of derivative security 87.4K shares
Sell / Disposition
6.7M Shares
From 6 Insiders
Open market or private sale 6.7M shares

Track Institutional and Insider Activities on JANX

Follow Janux Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells JANX shares.

Notify only if

Insider Trading

Get notified when an Janux Therapeutics, Inc. insider buys or sells JANX shares.

Notify only if

News

Receive news related to Janux Therapeutics, Inc.

Track Activities on JANX